All reports
Pharmaceutical
Obesity & Metabolic
Oral GLP-1: Foundayo (orforglipron) and the New Frontier
Code: NSC/PHRM/0001Published Mar 19, 2026Data window: 12 months
About this report
First wave of oral GLP-1 (Foundayo launched April 2026), adoption, eligibility expansion and impact on injectables.
Humans at the core of the analysis
Partner specialist firms, independent domain experts and our in-house analyst team: every report is written and reviewed by humans who cross-check signals, verify sources and prioritise what matters.
Key insights
Request the sample to discover the report's key insights.
Table of contents
The detailed table of contents is shared with the free sample.